Compare · HYFT vs NVO
HYFT vs NVO
Side-by-side comparison of MindWalk Holdings Corp. (HYFT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYFT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2450.6x HYFT ($74.7M).
- Over the past year, HYFT is up 139.4% and NVO is down 45.7% - HYFT leads by 185.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for HYFT).
- NVO has more recent analyst coverage (25 ratings vs 0 for HYFT).
- Company
- MindWalk Holdings Corp.
- Novo Nordisk A/S
- Price
- $1.59-5.62%
- $41.01-4.51%
- Market cap
- $74.7M
- $183.15B
- 1M return
- +31.82%
- -10.44%
- 1Y return
- +139.42%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HYFT
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
- SEC Form 6-K filed by MindWalk Holdings Corp.
- The Biology Came First.
- Amendment: SEC Form SCHEDULE 13G/A filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care